Stay updated on Dolutegravir for Initial HIV in Resource-limited Settings Clinical Trial
Sign up to get notified when there's something new on the Dolutegravir for Initial HIV in Resource-limited Settings Clinical Trial page.

Latest updates to the Dolutegravir for Initial HIV in Resource-limited Settings Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3. This is a versioning update and does not affect the study information or user-facing features.SummaryDifference0.1%

- Check14 days agoChange DetectedThe page now shows Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check43 days agoChange DetectedThe page adds Revision: v3.4.2 and removes a Notice about government funding status along with the previous Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check50 days agoChange DetectedAdded a government funding notice indicating possible processing delays and that the NIH Clinical Center is open. Updated the site revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check57 days agoChange DetectedUI updates include a glossary display toggle, and new labels: 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', plus 'No FEAR Act Data'. The previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.SummaryDifference0.2%

- Check93 days agoChange DetectedFooter now displays Revision: v3.3.3; the HHS Vulnerability Disclosure link and the Revision: v3.3.2 reference were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Dolutegravir for Initial HIV in Resource-limited Settings Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dolutegravir for Initial HIV in Resource-limited Settings Clinical Trial page.